trevena.com (TRVN) Year-over-year earnings per share growth for the last twelve months
The development of innovative analgesics for inpatient care guarantees Trevena, Inc. (TRVN) stable sales through hospital formularies, while the recruitment of leading neurobiologists is driven by financial bonuses for creating safe medications. The quarterly EPS growth rate reflects the dynamics of net income, where 0.00 expresses the latest level of the metric. Current hospital sales provide a modest effect while conditions are being established for major international licenses.
Summary analytical data breakdowns for trevena.com (TRVN)
- share price and expert price forecast:
- market capitalization details:
- book capitalization data:
- debt and solvency information:
Total Debt to Capital Trevena, Inc.|TRVN - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity Trevena, Inc|TRVN - Company Aggregate Debt|Debts to Book Capitalization Trevena, Inc.|TRVN - Company Long-Term Liabilities|Company Current Liabilities Trevena|Quick Liquidity Indicator trevena.com
- earnings and valuation multiples indicators:
TRVN - Profit After Payment of Taxes|Expected Profit Trevena, Inc.|TRVN - Company Value to Net Income|Projected Price to Earnings Trevena, Inc.|TRVN - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Trevena Inc.|TRVN - Operating profit before amortization|Earnings per share for the last twelve months Trevena|TRVN - Earnings per share for the last 12 months|Quarterly EPS earnings growth trevena.com|TRVN - Earnings per share growth rate in current year|Expected earnings per share growth for next year Trevena, Inc.
- revenue and sales details:
Summary company analysis:Trevena Inc - TRVN
Trevena, Inc. specializes in developing innovative non-opioid analgesics, investing in a high-paid staff of neuropharmacologists to navigate FDA stages. By analyzing the quarterly EPS trajectory, an investor assesses net income per share dynamics to distinguish organic business scaling from short-term cost savings, thereby determining the company's real resilience to inflationary pressure and its fundamental value.
Main competitors
BIIB: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Neurocrine Biosciences Inc (NBIX)|RGC (Regencell Bioscience Ltd) - Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Axsome Therapeutics, Inc. AXSM|Year-over-year net earnings per share growth for the last 12 months ACAD (ACADIA Pharmaceuticals Inc.)|XENE: Year-over-year net earnings per share trend for the last twelve months|Viking Therapeutics, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year net earnings per share change for the last twelve months Supernus Pharmaceuticals (SUPN)|CPRX: Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months DNLI (Denali Therapeutics)|HRMY: Quarterly EPS earnings growth|BHVN (Biohaven Pharmaceutical) - Year-over-year earnings per share growth for the last twelve months|Year-over-year earnings per share growth for the last twelve months Amylyx|Quarterly EPS earnings growth Trevi Corp|Quarterly EPS earnings growth PRAX|AVXL (anavex.com) - Year-over-year earnings per one share growth for the last 12 months|CeriBell Inc - Year-over-year net earnings per share growth for the last 12 months|PRTA (Prothena Corporation plc) - Year-over-year net earnings per share trend for the last twelve months|ALEC - Year-over-year earnings per share growth for the last twelve months|ANNX (Annexon Biosciences Inc.) - Year-over-year earnings per share growth for the last 12 months|OMER (omeros.com) - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last 12 months NGNE|Year-over-year net earnings per share growth for the last 12 months ACIU|Quarterly EPS earnings growth Voyager Pharma|Year-over-year net earnings per share growth for the last 12 months NMRA (Neumora Therapeutics, Inc.)|SCLX - Earnings per share growth in annualized terms for the last twelve months|Year-over-year earnings per share growth for the last twelve months Tevogen Bio TVGN|Alpha Cognition Corp (ACOG) - Earnings per share growth in annualized terms for the last twelve months|CGTX: Year-over-year net earnings per share growth for the last 12 months|Inhibikase Therapeutics, Inc. - Year-over-year earnings per share growth rate for the last twelve months|SAVA: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months ASRT|COYA (coyatherapeutics.com) - Quarterly EPS earnings growth|Vistagen (VTGN) - Year-over-year net earnings per share change for the last twelve months|Year-over-year net earnings per share growth for the last 12 months OVID (Ovid Rx)|Year-over-year net earnings per share change for the last twelve months Acumen Pharmaceuticals, Inc.|Quarterly EPS earnings growth CRVO (CervoMed Corporation)|Year-over-year earnings per share growth rate for the last twelve months ATHE (Alterity Therapeutics Ltd)|Clene Nanomedicine - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year pepgen.com (PEPG)|JUNS: Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last 12 months RLMD|ANVS (Annovis Bio Inc) - Quarterly EPS earnings growth|Year-over-year net earnings per share growth for the last 12 months Grace Therapeutics, Inc. (GRCE)|Quarterly EPS earnings growth AIFF|Year-over-year earnings per share growth rate for the last twelve months KLTO|Year-over-year earnings per share growth for the last twelve months neurosense-tx.com NRSN|Reviva Pharmaceuticals Holdings (RVPH) - Earnings per share growth in annualized terms for the last twelve months|MetaVia Inc. - Quarterly EPS earnings growth|Year-over-year net earnings per share change for the last twelve months NeurAxis Inc NRXS|HSDT (Helius Medical Technologies Inc.) - Year-over-year net earnings per share growth for the last 12 months|Passage Bio Inc. (PASG) - Quarterly EPS earnings growth|Year-over-year earnings per share growth for the last twelve months Neuphoria|Year-over-year net earnings per share growth for the last 12 months Minerva Neurosciences, Inc. (NERV)|Year-over-year earnings per share growth for the last twelve months Athira (ATHA)|Addex Therapeutics - Year-over-year earnings per share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Alzamend Neuro, Inc. ALZN|Cyclerion (CYCN) - Earnings per share growth in annualized terms for the last twelve months|PTIX - Year-over-year earnings per share growth for the last twelve months|Year-over-year net earnings per share change for the last twelve months Pasithea Therapeutics Corp KTTA|Cortigent, Inc. (CRGT) - Year-over-year earnings per share growth for the last twelve months|Avenue Therapeutics - Year-over-year earnings per one share growth for the last 12 months|BCLI (brainstorm-cell.com) - Quarterly EPS earnings growth|CARA: Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Chromocell Therapeutics Corp (CHRO)|ELYM (Eliem Therapeutics Inc.) - Year-over-year earnings per one share growth for the last 12 months|Quarterly EPS earnings growth ITCI (Intra-Cellular Therapies Inc.)|Net earnings per share growth for the trailing year Longboard Pharma|MRNS - Year-over-year earnings per share growth for the last twelve months|NKGen Biotech, Inc. (NKGN) - Year-over-year net earnings per share growth for the last 12 months|NRBO (NeuroBo Pharmaceuticals, Inc.) - Year-over-year net earnings per share growth for the last 12 months|Sage Therapeutics - Year-over-year earnings per one share growth for the last 12 months|Year-over-year earnings per share growth for the last twelve months Synaptogenix, Inc.|Vigil Neuroscience (VIGL) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth WENA|Quarterly EPS earnings growth cerevel.com (CERE)
